DCM
VRCA icon

DAFNA Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

DAFNA Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$145K Sell
23,750
-129,962
-85% -$810K 0.03% 85
2026
Q1 		$813K Sell
153,712
-19,739
-11% -$126K 0.19% 67
2025
Q4 		$1.44M Buy
+173,451
New +$961K 0.33% 55

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DAFNA Capital Management's VRCA Position: Q2 2026 in Review

DAFNA Capital Management reduced its Verrica Pharmaceuticals (VRCA) stake by 85% in Q2 2026, selling an estimated $810K and leaving 23,750 shares worth $145K. The position accounts for 0.03% of the portfolio, ranked #85.

DAFNA Capital Management first reported a position in VRCA in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.44M in Q4 2025. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • DAFNA Capital Management held 23,750 shares of Verrica Pharmaceuticals worth $145K as of Q2 2026.
  • DAFNA Capital Management sold 129,962 Verrica Pharmaceuticals shares in Q2 2026, an estimated $810K.
  • Verrica Pharmaceuticals made up 0.03% of DAFNA Capital Management's portfolio in Q2 2026, its #85 holding.
  • DAFNA Capital Management first reported a position in Verrica Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • DAFNA Capital Management's Verrica Pharmaceuticals position peaked at $1.44M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.